Documentos relacionados

1. Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity <i>via</i> inhibiting the deubiquitination activity of CSN5.
2. Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy.
3. Inhibition of Glutamine Utilization Synergizes with Immune Checkpoint Inhibitor to Promote Antitumor Immunity.
4. Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.
5. Design, synthesis and biological evaluation of new dihydropyridine derivatives as PD-L1 degraders for enhancing antitumor immunity.
6. ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion.
7. CD300ld on neutrophils is required for tumour-driven immune suppression.
8. Autologous patient-derived exhausted nano T-cells exploit tumor immune evasion to engage an effective cancer therapy.
9. A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells.
10. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis.